Shukra Pharmaceuticals: Unaudited financial results for the quarter ended 30th September 2026
Shukra Pharmaceuticals (SHUKRAPHAR) filed a disclosure titled "Unaudited financial results for the quarter ended 30th September 2026". The company is valued at about ₹3,511 crore.
What happened
Shukra Pharmaceuticals (SHUKRAPHAR) filed a disclosure with the exchanges on 4 November 2026 at 08:40 PM titled "Unaudited financial results for the quarter ended 30th September 2026".
Company snapshot
Shukra Pharmaceuticals is a small-cap company, with a market value of about ₹3,511 crore.
The stock last traded at ₹79.87, against a 52-week range of ₹40.06–₹84.2 (5.1% below the high).
Before this filing the shares had moved +29.2% over the month. Average daily turnover over the last 20 sessions was about ₹65.08 crore.
Promoters held 51.15% at the end of Q2 FY27, up 0.19% points from the previous quarter. Foreign institutions owned 0.00% and domestic institutions 0.11%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 5 | 1 | 0.02 |
| Q2 FY26 | 6 | 2.4 | 0.05 |
| Q3 FY26 | 39 | 20.4 | 0.47 |
| Q4 FY26 | 6 | -1.7 | -0.04 |
| Q1 FY27 | 24 | 15 | 0.34 |
What history shows
BCEIE's records show 1 previous results filing from the company since May 2026.
Market-wide, 10,790 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 4 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.